Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Related Keywords

Kevin Kalinsky ,Glenn Family Breast Center ,Division Of Medical Oncology ,Breast Cancer Research ,Department Of Hematology ,Winship Cancer Institute Of Emory University ,Emory University School Of Medicine ,Medical Oncology ,Emory University School ,Rand Glenn Family Chair ,Breast Medical Oncology ,Winship Cancer Institute ,Emory University ,